Established in 1901 in Jerusalem by three young pharmacists selling drugs in a small store

Size: px

Start display at page:

Download "Established in 1901 in Jerusalem by three young pharmacists selling drugs in a small store"

Elijah Miller
6 years ago
Views:

1 Teva overview 2011

2 Established in 1901 in Jerusalem by three young pharmacists selling drugs in a small store

3 More than 100 years later, we are among the top 15 pharmaceutical companies and the world leader in Generics

6 1 to 31 No. 1 generic pharmaceutical company Top 15 global pharmaceutical company About 63 Billion tablets manufactured in 2010 Operations in 60 countries Distribution of products to over 120 markets Global product portfolio of about 1,300 molecules About 47,000 employees in Teva $16 billion in sales and $4 billion in non GAAP net income in 2010 Strategic goal of $ 31 billion in sales by 2015 Employees as of Oct 14 st

7 Teva Worldwide presence 60 Locations Worldwide 7

8 New Logistics Center - Shoham, Israel March

9 Teva Worldwide production sites בעולם טבע אתרי ייצור תרופות CANADA USA UK IRELAND POLAND NETHERLANDS HUNGARY GERMANY CZECH CROATIA FRANCE ITALY MEXICO SPAIN ISRAEL CHINA INDIA PERU CHILE ARGENTINA 25 Countries 56 Pharma production sites 21 API production sites 9

10 New Sites - Opava, Czech Republic 7BN Tablets 10

11 New Sites - Debrecen, Hungary 10BN Tablets 11

12 Teva Organizational Structure President & CEO Research & Development Business Development Human Resources & Integration Finance Legal Quality Americas Europe EMIA Asia Teva Generics System Global Branded Products 12

13 2010 Financials Change Sales $M 13,899 16, % Operating Income $M 3,853 4, % Net Income $M 3,029 4, % * Operating income and net income are non-gaap results 13

14 Strong M&A track record Index, 1995= CAGR of 22% CAGR of 31% CoGenesys Infarmassa Sales Net income US / biopharma Bentley ratiopharm Peru Theramex Spain Europe Europe- WH Barr Tayio & TK 8,000 7,000 6,000 Pharmachemie Netherlands APS / Berk UK Sicor Global JK India / API Global Medilac (50%) Turkey Ivax Global Japan Cephalon USA 5,000 Biocraft Novopharm HPFC 4,000 3,000 Biogal Hungary US Canada, Hungary Copley US Italy Bayer Classics France Dorom Italy 2,000 ICI Pharbil Italy Netherlands 1,

Global leadership. keeping the gap 2010 Global l Peer Group Sales $16.1 1 B 1.9X $8.52 B $5.5 B $3.5 B $2.

15 Global leadership. keeping the gap 2010 Global l Peer Group Sales $ B 1.9X $8.52 B $5.5 B $3.5 B $2.2 B $1.9 B $1.7 B Teva Sandoz Mylan Watson Stada Ranbaxy Dr. Reddy Source: First Call and Company filings 15

16 Strong Growth Track Record Sales Net income* Operations Plants Employees** Market cap** $BN $Mil Countries Numbers Thousand $BN , *2010 Net income - Non-GAAP ** Market cap as of Dec 31 st

17 The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 17

18 Teva & Cephalon Deal - Multifaceted Expertise 2010 Revenue: $4.6B 2010 PF2010 Revenue: $7B 2015E Revenue: $9.2B

19 Towards 2015

20 On Track To Deliver Long-term Strategic Targets Long-term Strategic Plan: GENERICS ratiopharm: GX #1 in Europe Taiyo: leadership in Japan Infarmasa: expansion in LA DIVERSIFY TEVA Progress In 3 Directions BRANDED Cephalon: expansion/diversification Theramex: global expansion women s health OTC JV with P&G: leverage value in existing OTC business 20

21 Still Room for Growth in Generics? $ BN in 2015 GROWTH GROWTH GROWTH GROWTH Increasing opportunities in emerging generics markets People living i Healthcare longer and reforms and consuming more cost saving drugs initiatives $150bn of brands going off-patent in the next 5 years 21

22 Balanced Business Model Diversity Across Business Lines, Products and Geographies Higher GROWTH 70% Generic 30% Branded Higher MARGINS 22

23 Copaxone - leading MS globally Global in market sales, $ million Non-U.S. U.S. +17% +26% 3, % 2,826 1, % , , ,094 1,378 1,917 2, % Q4'09 Q4'10 * Due to rounding, numbers may not add up 23

24 Teva Branded - Multifaceted approach & expertise Azilect Respiratory Biosimilars Copaxone Innovative Pipeline New Product Licensing Women s Health 24

25 Loaded Branded Pipeline Innovative Respitatory Women s Health Biologics Marketed Products Copaxone Multiple Sclerosis & CIS Azilect - Parkinson s End Phase III Laquinimod Oral Multiple Sclerosis (Phase III) StemEx Hemato-oncological (Phase III) End Phase III TV-1011 (OGX-011) Prostate Cancer 1st line (Phase III) TV-1011 (OGX-011) Prostate Cancer 2nd line (Phase III) PolyHealTM - Chronic Wounds NexoBrid - Burns (Phase III) * TV-1011 (OGX-011) Lung Cancer (Phase III) QVAR - Inhaled Steroid Azilect MSA (phase II) DiaPep-277 Type I Diabetes (Phase III) ProAirTM BDP HFA Nasal (QNAZETM) Laquinimod Inhaled short acting beta-mimetic ti Rhinitis (Phase III) ** Crohn's disease (Phase II) Easi-Breathe products Asthma & COPD Seasonique / LoSeasoniqueTM Extended Regimen Contraception Plan B One-Step Emergency Contraception ParaGard Intrauterine Contraception EnjuviaTM Hormone Therapy TEV-TROPIN Growth Hormone Deficiency TevaGrastim / RatioGrastim / Biogrsatim - Hematology Eporatio / Biopoin - Hematology BFC Spiromax - Asthma/COPD (Phase III) Albuterol Spiromax - Asthma/COPD (Phase III) FP HFA MDI Asthma (Phase III) FCS HFA MDI Asthma (Phase III) NOMAC/E2 - Oral Contraception (Phase III) * DR-103 Contraception (Phase III) Oxybutynin Vaginal Ring Overactive Bladder (Phase III) Progesterone Vaginal Ring Infertility (Phase III) DR-102 Contraception (Phase III) Follirtopin alfa Gynecology / Andrology (Phase III) Glyco - PEG-G-CSF Hematology (Phase III) Neugranin Hematology (Phase III) * File submitted in EMA; ** Phase III completed in perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR). CT-011 Hemato-Oncological (Phase II) CT-011 Solid Tumor Oncology (Phase II) Laquinimod i - Lupus (Phase II) MultiGene Angio Critical Limb Ischemia (Phase II) FP Spiromax - Asthma (Phase III) FSC Spiromax - Asthma (Phase III) Vaginal Ring (undisclosed) Menopause product (undisclosed) Rituximab (Phase II) 2 Biosimilars projects (undisclosed) 25

26 Balance in Terms of Geography Sales 2010 = $16.1BN Sales 2015 = $31BN 14% International 22% International ti 24% Europe 62% North America 30% Europe 48% North America 26

27 Right on track towards 2015 goals Revenues Net Income Net Profit 2010 $16.1BN $4.1BN 24% 2015E* $31BN $6.8BN 22% * Net Income and Net Profit are Non-GAAP results 27

28 How we create value Growth Business High Financial Sustainable - Balanced model High Profitability Strength 28

AREA TOTALS OECD Composite Leading Indicators. OECD Total. OECD + Major 6 Non Member Countries. Major Five Asia. Major Seven.

AREA TOTALS OECD Composite Leading Indicators. OECD Total. OECD + Major 6 Non Member Countries. Major Five Asia. Major Seven. Reference series Composite leading indicators OECD Composite Leading Indicators AREA TOTALS 7-03- 19 OECD Total 19 OECD + Major 6 Non Member Countries 19 Major Seven 19 Major Five Asia 19 Euro area 19